Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical)
Link
http://link.springer.com/content/pdf/10.1007/s40265-019-01194-x.pdf
Reference39 articles.
1. El-Amm J, Aragon-Ching JB. The current landscape of treatment in non-metastatic castration-resistant prostate cancer. Clin Med Insights Oncol. 2019. https://doi.org/10.1177/1179554919833927 .
2. Esther J, Maughan BL, Anderson N, et al. Management of nonmetastatic castration-resistant prostate cancer: recent advances and future direction. Curr Treat Options Oncol. 2019. https://doi.org/10.1007/s11864-019-0611-z .
3. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494–503.
4. Janssen Pharmaceutical Companies. ErleadaTM (apalutamide): US prescribing information. 2018. http://www.fda.gov/ . Accessed 16 Aug 2019.
5. European Medicines Agency. Erleada (apalutamide): EU summary of product characteristics. 2019. http://www.ema.europa.eu/ . Accessed 16 Aug 2019.
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Concomitant Administration of Psychotropic and Prostate Cancer Drugs: A Pharmacoepidemiologic Study Using Drug–Drug Interaction Databases;Biomedicines;2024-09-01
2. Structural screening and molecular simulation identify potential ligands against the K700E hot spot variant and functional pockets of SF3B1 to modulate splicing in myelodysplastic syndrome;Heliyon;2024-06
3. RNA N6-methyladenosine-modified-binding protein YTHDF1 promotes prostate cancer progression by regulating androgen function-related gene TRIM68;European Journal of Medical Research;2023-12-02
4. Automation of Drug Discovery through Cutting-edge In-silico Research in Pharmaceuticals: Challenges and Future Scope;Current Computer-Aided Drug Design;2023-12
5. Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer;Journal of Medicinal Chemistry;2023-06-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3